Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Apr 12;76(15):1338-43.
doi: 10.1212/WNL.0b013e3182152844.

Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children

R Arya  1 , S Gulati, M Kabra, J K Sahu, V Kalra
Affiliations
Randomized Controlled Trial

Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children

R Arya et al. Neurology. .

Abstract

Objective: Gingival overgrowth is an important adverse effect of phenytoin (PHT) therapy, occurring in about half of the patients. This study aimed to evaluate the effect of oral folic acid supplementation (0.5 mg/day) for the prevention of PHT-induced gingival overgrowth (PIGO) in children with epilepsy aged 6-15 years on PHT monotherapy for 6 months.

Methods: This was a randomized, double-blind, placebo-controlled trial conducted at a tertiary level hospital from May 2008 to June 2009. Children aged 6-15 years started on PHT monotherapy within last 1 month were eligible for inclusion. Preexisting gingival overgrowth, use of other folic acid antagonists, and macrocytic anemia were exclusion criteria. Trial subjects were randomized to receive either folic acid or placebo. The primary outcome measure was incidence of any degree of gingival overgrowth after 6 months of PHT monotherapy. The trial was registered with clinicaltrials.gov (NCT00781196).

Results: A total of 120 children were recruited, 62 and 58, respectively, in folic acid and placebo arms. The 2 arms were comparable at baseline. Twenty-one percent of patients in the folic acid arm developed PIGO, as compared with 88% receiving placebo (p < 0.001). Absolute risk reduction of PIGO by folic acid was 67% (95% confidence interval 54%-80%), and relative risk reduction was 0.76.

Conclusions: Oral folic acid was found to decrease the incidence of PIGO in children on PHT monotherapy, in a statistically significant and clinically relevant manner.

Classification of evidence: This study provides Class I evidence that folic acid supplementation, 0.5 mg/day, is associated with prevention of gingival overgrowth in children taking PHT monotherapy.

PubMed Disclaimer

Figures

Figure
Figure. Flow of patients in the study
See this image and copyright information in PMC

References

    1. Merritt HH, Putnam TJ. Sodium diphenylhydantoinate in the treatment of convulsive disorders. JAMA 1938;111:1068–1073 - PubMed
    1. Kimball OP. The treatment of epilepsy with sodium diphenylhydantoinate. JAMA 1939;112:1244
    1. Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1972;34:898–906 - PubMed
    1. Seymour RA. Drug-induced gingival overgrowth. Adverse Drug React Toxicol Rev 1993;12:215–232 - PubMed
    1. Prasad VN, Chawla HS, Goyal A, Gauba K, Singhi P. Incidence of phenytoin induced gingival overgrowth in epileptic children: a six month evaluation. J Indian Soc Pedod Prev Dent 2002;20:73–80 - PubMed

Publication types

Associated data